Manassas, VA, June 19, 2017 – Metabiomics is proud to announce the completion of one of the largest case-controlled studies on the colorectal polyp microbiome. Titled “Metabiomics Neoplasia Clinical Research Study”, also referred to as MB-01 by Metabiomics, the study involved the recruitment of 232 average-risk patients that were visiting two Washington DC metro area colonoscopy clinics for routine screening colonoscopies.
Each patient contributed three samples, one stool sample with an easy-to-use sampling kit, one rectal swap taken by a gastroenterologist during the pre-colonoscopy consultation, and one biopsy sample which was collected during the colonoscopy. The cohort consisted of 87 females and 131 males of which 193 were Caucasian, 21 African American and 4 Asian Americans.
The samples are all in the process of being analyzed, including MultiTag(tm) Next-Generation DNA sequencing on an Ion Torrent Instrument as well as an advanced 16S rRNA phylogenetic analysis and machine learning pipeline with the goal of developing a predictive model for colorectal polyps.
Colon cancer kills more than 50,000 people per year in the U.S. It has been demonstrated that colon cancer can be prevented with early detection and removal of precancerous colon polyps. However, participation in CRC screening programs is very low, in large part, because programs rely on expensive and invasive colonoscopies that have to be performed at specialized clinics. Metabiomics aims to provide the healthcare system with an easy-to-use, non-invasive option for detecting colon polyps that can be used to optimize colonoscopy for performing polypectomy procedures.
About Metabiomics, Inc.
Metabiomics is an early stage molecular diagnostics company that is developing in-vitro diagnostics, screening tests, and health assays that leverage breakthroughs in next-generation DNA sequencing, computational systems biology, and human microbiome sciences. Over the past 10 years, the company’s founders have developed a powerful technology platform for interrogating the human gut microbiome. To learn more, visit us at www.metabiomics.com